BR0314893A - Vetor para vacina contra hpv e microrganismo transformado pelo vetor - Google Patents

Vetor para vacina contra hpv e microrganismo transformado pelo vetor

Info

Publication number
BR0314893A
BR0314893A BR0314893-9A BR0314893A BR0314893A BR 0314893 A BR0314893 A BR 0314893A BR 0314893 A BR0314893 A BR 0314893A BR 0314893 A BR0314893 A BR 0314893A
Authority
BR
Brazil
Prior art keywords
vector
hpv vaccine
human papillomavirus
complex
relates
Prior art date
Application number
BR0314893-9A
Other languages
English (en)
Inventor
Moon-Hee Sung
Ha-Ryoung Poo
Jong-Soo Lee
Chang-Min Jung
Seung-Pyo Hong
Chul-Joong Kim
Sue-Nie Park
Hyun-Mi Pyo
Original Assignee
Bioleaders Corp
Korea Res Inst Of Bioscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioleaders Corp, Korea Res Inst Of Bioscience filed Critical Bioleaders Corp
Publication of BR0314893A publication Critical patent/BR0314893A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"VETOR PARA VACINA CONTRA HPV E MICROORGANISMO TRANSFORMADO PELO VETOR". A presente invenção refere-se a vetores de expressão que podem produzir eficientemente proteína de virion capsídeo, proteína associada a tumores do papilomavírus humano sobre uma superfície microbial e variedades bacteriais ancorando tais vetores de superfície e o uso das variedades bacteriais ou de seus extratos, produtos purificados como vacinas complexas. Mais particularmente, a presente invenção refere-se a vetores de de superfície que contém um ou mais do que dois genes selecionados entre pgsB, pgsC e pgsA, codificando o complexo de sintetase de poli-<sym>-glutamato (pgsBCA) de uma variedade de Bacillus sp. âncoras e genes que codificam proteínas de virion capsídeo, proteínas associadas a tumor de papilomavírus humano e método de preparação dos mesmos.
BR0314893-9A 2002-10-17 2003-10-17 Vetor para vacina contra hpv e microrganismo transformado pelo vetor BR0314893A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20020063378 2002-10-17
PCT/KR2003/002163 WO2004035795A1 (en) 2002-10-17 2003-10-17 Vector for anti-hpv vaccine and transformed microorganism by the vector

Publications (1)

Publication Number Publication Date
BR0314893A true BR0314893A (pt) 2005-08-09

Family

ID=32105598

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314893-9A BR0314893A (pt) 2002-10-17 2003-10-17 Vetor para vacina contra hpv e microrganismo transformado pelo vetor

Country Status (7)

Country Link
US (2) US7425438B2 (pt)
JP (1) JP4549858B2 (pt)
KR (1) KR100609866B1 (pt)
CN (1) CN100543140C (pt)
AU (1) AU2003271215A1 (pt)
BR (1) BR0314893A (pt)
WO (1) WO2004035795A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425438B2 (en) * 2002-10-17 2008-09-16 Bioleaders Corporation Vector for anti-HPV vaccine and transformed microorganism by the vector
KR100469936B1 (ko) * 2003-06-04 2005-02-03 주식회사 바이오리더스 사스 바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물
KR20050079162A (ko) * 2004-02-04 2005-08-09 주식회사 바이오리더스 파보바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물
US20080160040A1 (en) * 2004-04-15 2008-07-03 Ghim Shin-Je Plant-produced compositions for treating papillomavirus infection and related methods
KR100517114B1 (ko) * 2005-02-25 2005-09-27 주식회사 바이오리더스 폴리감마글루탐산을 함유하는 면역보강제 조성물
WO2006126682A1 (ja) * 2005-05-27 2006-11-30 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute アルツハイマー病の予防・治療用ワクチン
AU2006295040A1 (en) * 2005-09-08 2007-04-05 Kentucky Bioprocessing, Llc Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications
WO2008115631A2 (en) * 2007-02-08 2008-09-25 University Of Louisville Research Foundation, Inc. Plant-produced compositions for treating papillomavirus infection and related methods
KR100857861B1 (ko) * 2007-10-15 2008-09-11 주식회사 바이오리더스 Ｍｙｏ－２ 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물
KR101471043B1 (ko) * 2009-01-08 2014-12-09 주식회사 바이오리더스 안정적인 항시적 고발현 자궁경부암 치료백신용 벡터 및 그에 의해 형질전환된 재조합 유산균
KR101564084B1 (ko) * 2009-01-08 2015-10-29 주식회사 바이오리더스 ｒｅｐＥ 변이유전자를 함유하는 항시적 고발현 벡터
KR101349291B1 (ko) * 2010-08-10 2014-01-10 한국생명공학연구원 고초균을 이용하여 자궁경부암 백신을 제조하는 방법
JP2014210747A (ja) 2013-04-19 2014-11-13 アンジェスＭｇ株式会社 細胞性免疫誘導能が改善された経口ワクチン
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN112430611A (zh) * 2020-11-30 2021-03-02 华南理工大学 一种经优化的玉米赤霉烯酮降解酶zhd-p编码基因、重组菌体、表面展示体系与应用
CN116875520B (zh) * 2023-07-12 2024-06-14 吉林农业大学 表达核糖体失活蛋白的乳酸菌及其在抗轮状病毒中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356797A (en) * 1991-11-15 1994-10-18 Board Of Regents, The University Of Texas Membrane expression of heterologous genes
WO1993024636A1 (en) * 1992-05-29 1993-12-09 The University Of British Columbia Use of protein oprf for bacterial cell surface expression of oligopeptides
FR2708622B1 (fr) * 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
EP1000157A1 (en) 1997-07-03 2000-05-17 University Technology Corporation Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy
WO1999029923A1 (en) 1997-12-05 1999-06-17 Tegal Corporation Plasma reactor with a deposition shield
FR2794370B1 (fr) * 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
JP2001017182A (ja) * 1999-07-09 2001-01-23 Nagase & Co Ltd ポリ−γ−グルタミン酸の製造方法
KR100366608B1 (ko) 2000-02-15 2003-01-09 마스터진(주) 형질전환 식물체로부터 생산된 재조합 인간 파필로마바이러스 백신
WO2003014360A1 (en) 2001-08-10 2003-02-20 Bioleaders Corporation SURFACE EXPRESSION VECTORS HAVING pgsBCA, THE GENE CODING POLY-GAMMA-GLUTAMATE SYNTHETASE, AND A METHOD FOR EXPRESSION OF TARGET PROTEIN AT THE SURFACE OF MICROORGANISM USING THE VECTOR
US7425438B2 (en) * 2002-10-17 2008-09-16 Bioleaders Corporation Vector for anti-HPV vaccine and transformed microorganism by the vector

Also Published As

Publication number Publication date
JP4549858B2 (ja) 2010-09-22
WO2004035795A1 (en) 2004-04-29
US20090117151A1 (en) 2009-05-07
US7425438B2 (en) 2008-09-16
JP2006502732A (ja) 2006-01-26
KR100609866B1 (ko) 2006-08-09
CN100543140C (zh) 2009-09-23
KR20040034511A (ko) 2004-04-28
US7871816B2 (en) 2011-01-18
US20050249752A1 (en) 2005-11-10
AU2003271215A1 (en) 2004-05-04
AU2003271215A8 (en) 2004-05-04
CN1705747A (zh) 2005-12-07

Similar Documents

Publication Publication Date Title
BR0314893A (pt) Vetor para vacina contra hpv e microrganismo transformado pelo vetor
MX2022013255A (es) Constructos de arn y usos de los mismos.
MY139031A (en) Vaccine composition comprising virus-like particles of human papillomavirus
MXPA02005639A (es) Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
EE05633B1 (et) Muundatud vaktsiiniaviirus Ankara (MVA), sellega nakatatud peremeesrakk ning seda sisaldav farmatseutiline kompositsioon, MVA valmistamine ja raviotstarbeline kasutamine
BRPI0407877A (pt) conjugado de peptìdeo-proteìna, vacina para a prevenção ou melhora da infecção pelo vìrus influenza, e, método para induzir um resposta imune em um paciente
PL398576A1 (pl) Preparaty szczepionek, preparaty farmaceutyczne, atenuowany wirus grypy, sposoby szczepienia, sposoby zapobiegania chorobie zakaznej, sposoby leczenia lub profilaktyki nowotworów, kompozycje szczepionek i kompozycje farmaceutyczne
BR0210216A (pt) Holotoxina do cólera imunogênica, mutante (ct-crm), composição imunogênica, métodos para aumentar a resposta imune de um hospedeiro vertebrado a um antìgeno, e para produzir uma holotoxina do cólera imunogênica, mutante, sequência ou molécula de ácido nucleico isolado e purificado, célula hospedeira, e, uso de uma holotoxina do cólera mutante
BR0316158A (pt) Vacina de vetor adenoviral
EP1594536A4 (en) ADJUVANT INFLUENZA VACCINE
HUP0203056A1 (hu) Vakcinakészítmény
MY125202A (en) Vaccine
HK1052629A1 (en) Proteosome influenza vaccine
BR9712852A (pt) Plasmìdeo, composição, processo de imunização de um indivìduo contra um patógeno, vacina recombinante, patógeno vivo atenuado, proteìna bl-1 substancialmente pura, vetor recombinante de expressão, e, anticorpo isolado
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
NO20031159D0 (no) Melkesyrebakterier som er i stand til å redusere et individs tendens til åutvikle allergiske reaksjoner
WO2023094713A3 (en) Coronavirus vaccine
BRPI0411393A (pt) vetor de expressão da superfìcie celular do antìgeno do vìrus sars e microorganismos transformados pelo vetor
EP3922724A4 (en) RECOMBINANT VECTOR WITH IMMUNOGENIC PROTEIN OF SWINE AFRICAN FEVER VIRUS, RECOMBINANT BACTERIA AND THEIR USES
MX2022016287A (es) Secuencias de acidos nucleicos y de aminoacidos de adenovirus de gorila, vectores que contienen las mismas y usos de las mismas.
CY1107560T1 (el) Ζωντανα εξασθενημενα βακτηρια για χρηση σε εμβολιο
NO20051561L (no) Nukleinsyremolekyler som koder for humant papillomavirus og anvendelse av disse i vaksine.
MX2022014248A (es) Vacunas para la papilomatosis respiratoria recurrente y metodos para usar estas.
BR0115646A (pt) Composição, dispositivo de liberação de partìculas, uso de uma composição, e, método para intensificar uma resposta imune contra um antìgeno de interesse em um paciente
ATE494377T1 (de) Vakzine gegen ipnv die aus hefezellen isoliert werden

Legal Events

Date Code Title Description
B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: NAO CONHECIDA A PETICAO NO 018060052898/SP DE 26/05/2006 POR MOTIVO DE HAVER PETICAO DE EXAME ANTERIOR VALIDA, EM VIRTUDE DO DISPOSTO NO ART. 219 INCISO II DA LPI.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08E Application fees: payment of additional fee required [chapter 8.5 patent gazette]

Free format text: COMPLEMENTAR A RETRIBUICAO DA 9A,10A E 11A ANUIDADES DE ACORDO COM A TABELA VIGENTE, REFERENTE AS GUIAS DE RECOLHIMENTO 221113010406, 221208563160 E 221400341870.

B25C Requirement related to requested transfer of rights

Owner name: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECH

Free format text: A FIM DE ATENDER A(S) TRANSFERENCIA(S), REQUERIDA(S) ATRAVES DA PETICAO NO 18140001483, DE 22/01/2014, E NECESSARIO COMPLEMENTAR O VALOR DA GUIA DE RECOLHIMENTO CORRESPONDENTE, POIS O INTERESSADO NAO E BENEFICIARIO DA TAXA REDUZIDA.

B25A Requested transfer of rights approved

Owner name: BIOLEAOERS CORPORATION (KR)

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]